AstraZeneca and Daiichi Sankyo’s Datroway drug has been approved in the U.S. to treat adult patients with non-small cell lung cancer. British pharmaceutical company AstraZeneca said Tuesday that the ...

AstraZeneca and its partner Daiichi Sankyo have won approval from U.S. regulators for their precision drug Datroway to treat a type of lung cancer, marking the first approval of the therapy in this ...

Datroway is used to treat an advanced form of non-small cell lung cancer in adults who had received prior treatment.

The trove of more than 200 letters is part of a pledge of transparency from the agency, with the intention to increase public ...

Daiichi Sankyo has more than 120 years of experience and scientific expertise. In 2019, they entered the oncology market in the UK, through a ground-breaking collaboration with AstraZeneca.

Daiichi Sankyo is a commercial-stage biopharmaceutical company that is in strong financial health. As of fiscal 2024, it had a debt/EBITDA ratio of 0.3 times and over JPY 700 billion in cash and ...

Additionally, Daiichi Sankyo is banking on its ADC platform to target specific antigens and proteins as it explores more treatment options in its pipeline, including patritumab deruxtecan, ifinatamab ...

On top of being Enhertu’s first foray into DTC marketing, the campaign represents “the first DTC that we’ve developed at Daiichi Sankyo for any of our oncology products," Dan Switzer, head ...

PE: What are the benefits that Daiichi Sankyo sees from participating in this? Switzer: I'll start with the benefits internally as an organization. We are a global pharmaceutical company, but our ...

AstraZeneca- Daiichi Sankyo's Multi-Billion Dollar Cancer Drug Shows Superior Efficacy Across Broad HER2 Positive Metastatic Breast Cancer Patients ...

AstraZeneca and Daiichi Sankyo’s Datroway drug has been approved in the U.S. to treat adult patients with non-small cell lung cancer. British pharmaceutical company AstraZeneca said Tuesday that ...